FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: **BioMark Diagnostics Inc.** (the "Issuer").

Trading Symbol: **BUX**

Date: **December 31, 2019**

1. New Options Granted:

Date of Grant: December 31, 2019

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Andrew W Maksymuik	Scientific Advisor	No	200,000	0.30	Dec 31, 2024	No
Donald Wayne Miller	Scientific Advisor	No	200,000	0.30	Dec 31, 2024	No
Paramjit Singh Tappia	Scientific Advisor	No	100,000	0.30	Dec 31, 2024	No
Daniel Samuel Sitar	Scientific Advisor	No	100,000	0.30	Dec 31, 2024	No
Horacio Bach	Scientific Advisor	No	50,000	0.30	Dec 31, 2024	No
Richard William Robertson	Scientific Advisor	No	75,000	0.30	Dec 31, 2024	No
John Yoo	Scientific Advisor	No	40,000	0.30	Dec 31, 2024	No
Shu Chun Li	Consultant	No	50,000	0.30	Dec 31, 2024	No
Mohamed Omer Ali Quwaa	Consultant	No	50,000	0.30	Dec 31, 2024	No
Tomas Raycove	Consultant	No	20,000	0.30	Dec 31, 2024	No
Amanuel Isack	Consultant	No	10,000	0.30	Dec 31, 2021	No
Mustafa Hussein Mubarak	Consultant	No	10,000	0.30	Dec 31, 2021	No
Navneet Singh	Consultant	No	10,000	0.30	Dec 31, 2021	No
Rahul Sarangal	Consultant	No	10,000	0.30	Dec 31, 2021	No
Sonil Gurbaksh Tappia	Consultant	No	20,000	0.30	Dec 31, 2021	No
Alfred R. Berkeley III	Advisor	No	200,000	0.30	Dec 31, 2024	No
Brian Kai-Ming Cheng	Director	Yes	150,000	0.30	Dec 31, 2024	No
Bramhanand Ramjiawan	Director	Yes	250,000	0.30	Dec 31, 2024	No
Rashid Ahmed Bux	CEO	Yes	1,500,000	0.30	Dec 31, 2024	No
Guoyu Huang	Interim CFO	Yes	750,000	0.30	Dec 31, 2024	No
		TOTAL	**3,795,000**			

Total Number of optioned shares proposed for acceptance: **3,795,000**

2. Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares[1]	Exercise Price	Original Date of Grant	Expiry Date
	1,100,000	$0.15	September 15, 2017	September 15, 2020
	250,000	$0.15	June 15, 2017	June 15, 2022
Total	1,350,000			

(1) Set out number of optioned shares for each grant with different terms.

3. Additional Information

(a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

The new option plan was approved by shareholders at Annual General Meeting on December 20, 2019.

(b) State the date of the news release announcing the grant of options.

December 31, 2019.

(c) State the total issued and outstanding share capital at the date of grant or amendment.

As of the date of grant, a total of 72,313,729 common shares of the Issuer are issued and outstanding.

(d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

The aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options represent 7.11% of the issued and outstanding shares of Issuer.

(e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

2,086,372

(f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

$0.30.

(g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

Not Applicable.

4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated: December 31, 2019

Rashid Ahmed Bux_____
Name of Director or Senior Officer

*"Rashid Ahmed Bux"*_____
Signature

CEO_____
Official Capacity